NCT03907475 2026-03-18
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
10 trialsNCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02412670 2023-07-10
Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT02377752 2021-02-17
A Study of Olaratumab in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02677116 2020-05-20
A Study of Olaratumab Alone and in Combination With Standard Chemotherapies in Children With Cancer
Eli Lilly and Company
Phase 1 Completed
NCT00305084 2019-10-04
Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
AGC Biologics S.p.A.
Phase 1 Completed
NCT01031420 2019-09-17
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Fox Chase Cancer Center
Phase 2 Completed
NCT00124956 2017-09-11
Doxorubicin Pharmacokinetic (PK) Study
Boston Children's Hospital
Phase 1/2 Withdrawn
NCT00798252 2015-07-07
Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers
Bristol-Myers Squibb
Phase 1 Completed
NCT00022178 2013-09-20
Combination Chemotherapy in Treating Patients With Metastatic Cancer of an Unknown Site of Origin
National Cancer Institute (NCI)
Phase 3 Unknown